Atlas Trials

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Clinical trial NCT03728361 · COMPLETED

Trial details

NCT number
NCT03728361
Sponsor
Dwight Owen
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine CarcinomaMetastatic Neuroendocrine CarcinomaNeuroendocrine CarcinomaRecurrent Small Cell Lung CarcinomaRefractory Small Cell Lung CarcinomaLung Cancer Stage IVLarge Cell Neuroendocrine CarcinomaNeuroendocrine TumorsSmall Cell Lung Cancer MetastaticSmall-cell Lung Cancer
Start date
2018-12-31
Primary completion
2025-12-02
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.